Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review

被引:98
作者
Ben Bouazza, Youssef [1 ,5 ]
Chiairi, Ibrahim [1 ]
El Kharbouchi, Ouiam [3 ]
De Backer, Lesley [2 ]
Vanhoutte, Greetje [2 ]
Janssens, Annelies [1 ,2 ,4 ]
Van Meerbeeck, Jan P. [1 ,2 ,4 ]
机构
[1] Antwerp Univ, Fac Med & Hlth Care, Univ Pl 1, B-2610 Antwerp, Belgium
[2] Antwerp Univ Hosp, MOCA, Wilrijkstr 10, B-2650 Edegem, Belgium
[3] Antwerp Univ Hosp, Dept Med Oncol, Wilrijkstr 10, B-2650 Edegem, Belgium
[4] Antwerp Univ Hosp, Dept Pulmonol & Thorac Oncol, Wilrijkstr 10, B-2650 Edegem, Belgium
[5] Rietbeemd 36, NL-4907 ED Oosterhout, Netherlands
关键词
Lung cancer; Patient-reported outcomes; Patient-reported outcome measures; Health-related quality of life; Questionnaires; Quality improvement; QUALITY-OF-LIFE; SF-36 HEALTH SURVEY; FUNCTIONAL ASSESSMENT; EUROPEAN-ORGANIZATION; CLINICAL-PRACTICE; THERAPY-LUNG; CARE; RELIABILITY; VALIDITY; TRIALS;
D O I
10.1016/j.lungcan.2017.09.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is often associated with a poor quality of life, as reflected by patient-reported outcome measures (PROMs). The aim of this paper is to describe and compare the PROMs that are available. In this manuscript, we review the impact of PROMs on the management of lung cancer. Quality of the study and risk of bias were assessed using the appraisal tools recommended by the Dutch Cochrane Center. Out of 51 studies included in this review, ten instruments were identified and categorized as either generic, cancer- or lung cancer-specific. PROMs are primarily applied in scientific research to compare the therapy outcomes and in drug development to support labeling claims. The interest for the routine use of PROMs in daily practice is growing, which has positive effects on the communication with the patient, mutual decision making and the monitoring and managing of the patient. Besides that, PROMs have an independent prognostic value for survival in lung cancer and economic evaluations can be conducted using their results. Electronic platforms simplify the implementation of PROMs in the daily clinic. The EORTC QLQ-C30 and its lung cancer-specific module QLQ-LC13 are the most frequently used instruments in lung cancer patients. PROMs have the potential to improve the quality of care with a proper implementation in the routine practice. PROMS are needed to value and understand the experience of the patient.
引用
收藏
页码:140 / 151
页数:12
相关论文
共 65 条
  • [21] THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE
    CELLA, DF
    TULSKY, DS
    GRAY, G
    SARAFIAN, B
    LINN, E
    BONOMI, A
    SILBERMAN, M
    YELLEN, SB
    WINICOUR, P
    BRANNON, J
    ECKBERG, K
    LLOYD, S
    PURL, S
    BLENDOWSKI, C
    GOODMAN, M
    BARNICLE, M
    STEWART, I
    MCHALE, M
    BONOMI, P
    KAPLAN, E
    TAYLOR, S
    THOMAS, CR
    HARRIS, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 570 - 579
  • [22] A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting
    Chen, Jack
    Ou, Lixin
    Hollis, Stephanie J.
    [J]. BMC HEALTH SERVICES RESEARCH, 2013, 13
  • [23] A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
    Cherny, N. I.
    Sullivan, R.
    Dafni, U.
    Kerst, J. M.
    Sobrero, A.
    Zielinski, C.
    de Vries, E. G. E.
    Piccart, M. J.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (08) : 1547 - 1573
  • [24] Health-Related Quality of Life in Non-Small-Cell Lung Cancer: An Update of a Systematic Review on Methodologic Issues in Randomized Controlled Trials
    Claassens, Lily
    van Meerbeeck, Jan
    Coens, Corneel
    Quinten, Chantal
    Ghislain, Irina
    Sloan, Elizabeth K.
    Wang, Xin Shelly
    Velikova, Galina
    Bottomley, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 2104 - 2120
  • [25] Cleeland CS, 2000, CANCER-AM CANCER SOC, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO
  • [26] 2-V
  • [27] Is late diagnosis of lung cancer inevitable? Interview study of patients' recollections of symptoms before diagnosis
    Corner, J
    Hopkinson, J
    Fitzsimmons, D
    Barclay, S
    Muers, M
    [J]. THORAX, 2005, 60 (04) : 314 - 319
  • [28] Health-related quality of life questionnaires in lung cancer trials: A systematic literature review
    Damm K.
    Roeske N.
    Jacob C.
    [J]. Health Economics Review, 3 (1) : 1 - 10
  • [29] International lung cancer trends by histologic type:: male:female differences diminishing and adenocarcinoma rates rising
    Devesa, SS
    Bray, F
    Vizcaino, AP
    Parkin, DM
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (02) : 294 - 299
  • [30] Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
    Dueck, Amylou C.
    Mendoza, Tito R.
    Mitchell, Sandra A.
    Reeve, Bryce B.
    Castro, Kathleen M.
    Rogak, Lauren J.
    Atkinson, Thomas M.
    Bennett, Antonia V.
    Denicoff, Andrea M.
    O'Mara, Ann M.
    Li, Yuelin
    Clauser, Steven B.
    Bryant, Donna M.
    Bearden, James D., III
    Gillis, Theresa A.
    Harness, Jay K.
    Siegel, Robert D.
    Paul, Diane B.
    Cleeland, Charles S.
    Schrag, Deborah
    Sloan, Jeff A.
    Abernethy, Amy P.
    Bruner, Deborah W.
    Minasian, Lori M.
    Basch, Ethan
    [J]. JAMA ONCOLOGY, 2015, 1 (08) : 1051 - 1059